A question about Seattle care
What counts as useful evidence?
Ask what the record actually shows. A study, a product approval and a professional licence answer different questions.
Ask whether the evidence matches the offer.
Ask for a study of the exact medicine and the concern being discussed. Ask who took part and what the study found.
A study’s headline leaves those questions open. Bring the full paper into the conversation if you have it.
As of September 26, 2026, FDA identifies claims that compounded drugs are proven to give the same results as approved drugs as misleading. A
Compounded means made to order. Evidence about an approved product does not prove a made-to-order medicine gives the same results.
A study
What was tested, and in whom?
A product record
What exact medicine was reviewed?
A state record
What licence does this person hold?
Ask the clinician how the record supports the proposed care.
An advisory meeting is not a new rule.
FDA is the Food and Drug Administration. An advisory committee is a group formed to advise the agency.
The July 23–24, 2026 meeting discussed whether seven peptide ingredients, including BPC-157, should join FDA’s ingredient list for ordinary pharmacies. B
BPC-157 is an ingredient name you may see in an offer. A meeting about adding it to a list is not permission to use it.
The official vote record for those discussions was still unpublished by FDA as of September 26, 2026.
A committee vote is advice. Changing that ingredient list requires FDA to publish a proposed rule, ask for public comments and then issue a final rule.
The list, called the 503A Bulks List, is one way an ingredient can meet federal rules for pharmacies making medicine for a named patient. Other ways concern an ingredient’s published quality standard or its use in an approved drug.
Ask the pharmacy to show which rule the ingredient meets and where FDA records support that answer.
Check FDA’s pharmacy ingredient pageA headline about that meeting therefore cannot establish that a pharmacy may now prepare a particular peptide.
A warning letter has limits too.
In information checked September 17, 2026, FDA says later replies and discussions with the business can change the issues in a warning letter. C
The letter describes FDA’s concerns when it was written. It is not a court’s decision.
Search the business name in FDA’s warning-letter database. Check for a posted response or a letter closing the matter.
Search FDA’s warning lettersNotes for this chapter
- A
FDA: claims about equivalent results for compounded medicines.
Read the source - B
FDA: material published for the peptide advisory meeting.
Read the source - C
FDA: the searchable warning-letter database and its limits.
Read the source